CHICAGO — Precision medicine in lung cancer is making a big impact at this year’s ASCO meeting. Rare mutations in lung tumors discovered through genetic screening are leading to the development of highly targeted drugs. And these drugs are shrinking tumors in patients not helped by current treatments.
Two case studies: A drug called BLU-667 from the biotech Blueprint Medicines (BPMC) caused tumors to shrink in 60% of patients with lung tumors containing an alteration to a gene called RET. These patients entered the clinical trial after standard chemotherapy stopped working.
About the Author Reprints
